Astria Therapeutics (ATXS) AI Stock Analysis

• Market Cap: $365.13M
• Dividend Yield: N/A
• Average Volume (3M): 251.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: N/A
• EPS Growth: 4.90%
• Country: US
• Employees: 59
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -2.09
• Shares Outstanding: 56,434,220
• 10 Day Avg. Volume: 299,394
• 30 Day Avg. Volume: 251,819
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $26.29
• Price Target Upside: 295.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

Astria Therapeutics displays financial stability with a strong balance sheet but faces significant risks due to zero revenue and increasing losses. The technical indicators show downward momentum. Promising developments in its drug pipeline and strategic corporate actions provide some optimism, balancing out the speculative nature of its stock.

Positive Factors

Clinical Development

The initiation of the Phase 3 ALPHA-ORBIT trial with navenibart for hereditary angioedema (HAE) presents a promising prophylactic therapy.

Financial Stability

Astria ended the quarter financially strong with $328.1 million in cash, which management believes will be sufficient to fund its current operating plan into mid-2027.

Negative Factors

Cash Burn

Annualized cash burn is significant, with a burn rate of $117 million and approximately 2.5 years of cash remaining.

Astria Therapeutics Business Overview & Revenue Model

Company Description

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.

How the Company Makes Money

Astria Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and potential royalties on sales of successfully developed drugs. Additionally, Astria Therapeutics may receive funding through grants and research collaborations. The company's revenue model typically involves significant investment in research and development, with potential returns materializing upon regulatory approval and market launch of its therapies.

Astria Therapeutics Financial Statement Overview

Summary

Astria Therapeutics is in an early-stage biotech phase with no revenue and ongoing R&D investments. The balance sheet is equity-funded, offering some stability, but persistent losses and negative cash flow highlight the need for successful product development and strategic financing.

Income Statement

Astria Therapeutics has consistently reported zero revenue, leading to no gross or net profit margins. The company's EBIT and EBITDA margins are negative, reflecting ongoing losses, which is typical for early-stage biotechs focused on R&D without commercial products yet.

Balance Sheet

The balance sheet reveals moderate leverage with a low debt-to-equity ratio. The equity ratio is strong, indicating a solid capital structure primarily funded by equity. However, persistent losses could erode equity over time, posing a risk to financial stability.

Cash Flow

Cash flow from operations is negative, indicative of cash burn typical in biotech. The company relies heavily on financing activities to maintain liquidity. Free cash flow remains negative, showing the need for continued financial support to sustain operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	-26.00K
	EBIT
-100.97M	-83.03M	-53.50M	-194.98M	-37.44M	-27.09M
	EBITDA
-116.17M	-83.03M	-53.50M	-194.98M	-37.44M	-26.27M
	Net Income Common Stockholders
-100.04M	-72.89M	-50.16M	-30.17M	-37.06M	-26.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
37.57M	246.53M	226.44M	125.51M	44.93M	36.24M
	Total Assets
39.17M	254.67M	230.63M	127.51M	47.46M	41.78M
	Total Debt
0.00	329.00K	939.00K	365.00K	1.05M	2.25M
	Net Debt
-15.29M	-175.20M	-19.59M	-86.14M	-23.88M	-7.65M
	Total Liabilities
4.23M	11.55M	9.42M	5.20M	6.79M	6.06M
	Stockholders Equity
34.94M	243.12M	221.22M	122.31M	40.67M	35.72M
Cash Flow		Free Cash Flow
-94.43M	-68.47M	-43.62M	-30.17M	-32.52M	-26.58M
	Operating Cash Flow
-94.09M	-68.44M	-43.53M	-30.15M	-32.48M	-26.57M
	Investing Cash Flow
-190.16M	135.05M	-167.13M	-12.55M	6.30M	-4.08M
	Financing Cash Flow
245.18M	88.40M	144.72M	104.28M	40.86M	25.62M

Astria Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXS, the sentiment is Neutral. The current price of 6.64 is above the 20-day moving average (MA) of 6.55, below the 50-day MA of 7.26, and below the 200-day MA of 9.77, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 71.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ATXS.

Astria Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATXS	51 Neutral	$365.13M	―	-38.03%	―	―	4.90%
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
PRQR	47 Neutral	$190.93M	―	-67.62%	―	346.02%	28.96%
CRSP	46 Neutral	$3.63B	―	-19.20%	―	-89.95%	-123.71%
SGMO	42 Neutral	$206.96M	―	-156.42%	―	-74.04%	48.16%
EDIT	39 Underperform	$125.29M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$962.71M	―	-54.00%	―	59.55%	3.09%

Astria Therapeutics Corporate Events

Astria Therapeutics Unveils Phase 3 Trial for Navenibart

Astria Therapeutics has announced the design of the ALPHA-ORBIT Phase 3 clinical trial for navenibart, a treatment for hereditary angioedema, which will feature both every 3- and 6-month treatment arms. This trial aims to support global registration and is expected to initiate in Q1 2025. The company is pioneering flexible dosing options to potentially make navenibart a market-leading choice for HAE therapy, and the trial design incorporates feedback from regulatory authorities and collaboration with patients and physicians.

Astria Therapeutics Expands Stock Incentive Plan

Astria Therapeutics, Inc. has amended its 2022 Inducement Stock Incentive Plan to increase the shares of common stock reserved for issuance from 1,700,000 to 2,800,000. This amendment, made without stockholder approval, aims to attract new talent by offering stock awards to individuals not previously employed by the company, potentially strengthening its workforce and aligning employee interests with those of shareholders.